IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v18y2021i13p6952-d584476.html
   My bibliography  Save this article

The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences

Author

Listed:
  • Olga Barszczewska

    (Department of Management and Logistics in Healthcare, Medical University of Lodz, 90-131 Lodz, Poland)

  • Anna Piechota

    (Department of Insurance, University of Lodz, 90-001 Lodz, Poland)

Abstract

Biosimilars are cheaper than original drugs and are thus of interest to the public. The aim of this article is to assess the benefits of introducing more than one biosimilar for the same substance (active pharmaceutical ingredient, API). The hypothesis is that the introduction of successive biosimilars of a specific original drug reduces the price of the selected API. The study focuses on drug prices varying with the successive arrival of new biosimilars. Three drugs that have at least three reimbursed biosimilars on the market were selected, two from the same therapeutic group (adalimumab and infliximab) and one (trastuzumab) representing another class of drugs. The following data were analyzed: price variation after the introduction of the first, second, and third biosimilar, and the average price reduction for all three biosimilars. Additionally, a literature review was conducted. The reimbursement of each new biosimilar is beneficial since it is associated with a price reduction in percentage terms. However, the first biosimilar brought about the greatest savings due to the higher initial prices of the original drugs and to Polish reimbursement rules. This article is helpful for when taking healthcare decisions regarding the pricing of and reimbursement for new biosimilars.

Suggested Citation

  • Olga Barszczewska & Anna Piechota, 2021. "The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences," IJERPH, MDPI, vol. 18(13), pages 1-13, June.
  • Handle: RePEc:gam:jijerp:v:18:y:2021:i:13:p:6952-:d:584476
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/18/13/6952/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/18/13/6952/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Olga Barszczewska & Anna Piechota & Jadwiga Suchecka, 2020. "Management of the National Drug Administration Through the Use of Biosimilar Medicines. Expenditures, Numbers of Reimbursed Packages and Shares of Biosimilar Products in the Infliximab Market a Year P," Problemy Zarzadzania, University of Warsaw, Faculty of Management, vol. 18(89), pages 121-138.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:18:y:2021:i:13:p:6952-:d:584476. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.